Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia.

Human immunodeficiency virus Macrophage polarization Microbiome Pneumocystis jirovecii pneumonia Th1-predominance

Journal

Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 25 01 2022
revised: 18 03 2022
accepted: 03 04 2022
pubmed: 3 5 2022
medline: 14 7 2022
entrez: 2 5 2022
Statut: ppublish

Résumé

While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of 30%-75%. The pathophysiological mechanism of non-HIV PCP is quite different from that of HIV-PCP. Aging, underlying disease, dysbiotic gut microbiome, and Th1 predominance, leads to macrophagic polarization shifting from M2 to M1. These cause dysregulation in the host immunity against P. jirovecii, resulting in severe lung injury and a high mortality rate among non-HIV PCP patients. This review describes poor prognostic factors, an issue of predictive values used for general pneumonia practice, and new aspects, including the dysbiosis of the gut microbiome and macrophagic polarization in the treatment of non-HIV PCP.

Identifiants

pubmed: 35501264
pii: S2212-5345(22)00046-6
doi: 10.1016/j.resinv.2022.04.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

522-530

Informations de copyright

Copyright © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest The authors declare that they have no conflict of interest.

Auteurs

Nobuhiro Asai (N)

Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan; Department of Pathology, University of Michigan, Ann Arbor, MI, 48109, USA.

Shinji Motojima (S)

Department of Rheumatology & Allergy, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan.

Yoshihiro Ohkuni (Y)

Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan.

Ryo Matsunuma (R)

Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan.

Tamao Nakashita (T)

Department of Rheumatology & Allergy, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Kanagawa, Japan.

Norihiro Kaneko (N)

Department of Pulmonology, Kameda Medical Center, Kamogawa, Chiba, Japan.

Hiroshige Mikamo (H)

Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan. Electronic address: mikamo@aichi-med-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH